BridgeBio Pharma, Inc. Annual Operating Income (Loss) in USD from 2017 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
BridgeBio Pharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2017 to 2023.
  • BridgeBio Pharma, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$192M, a 21.6% decline year-over-year.
  • BridgeBio Pharma, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$544M, a 2.65% increase year-over-year.
  • BridgeBio Pharma, Inc. annual Operating Income (Loss) for 2023 was -$607M, a 18.6% decline from 2022.
  • BridgeBio Pharma, Inc. annual Operating Income (Loss) for 2022 was -$512M, a 11.2% increase from 2021.
  • BridgeBio Pharma, Inc. annual Operating Income (Loss) for 2021 was -$577M, a 21.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$607M -$95.2M -18.6% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 -$512M +$64.4M +11.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 -$577M -$102M -21.5% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
2020 -$474M -$208M -78.2% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-23
2019 -$266M -$82.6M -45% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-25
2018 -$184M -$140M -319% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 -$43.9M Jan 1, 2017 Dec 31, 2017 10-K 2020-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.